Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months To evaluate the immunogenicity of two 0.25 mL IM doses of Fluad or Fluzone influenza vaccines in terms of post-vaccination geometric mean titers (GMTs), seroprotection rates and seroconversion rates, ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III multi-center, open-label, randomized study of the efficacy of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+ ) chronic myelogenous leukemia in chronic phase (CML - CP) who have suboptimal cytogenetic response (CyR) on imatinib To evaluate the complete cytogenetic response (CCyR ) rate at 12 months of nilotinib compared to imatinib in adult patients with Ph+ CML in CP who have a suboptimal cytogenetic response to imatinib.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and safety study of QAW039 in the treatment of patients with moderate to severe atopic dermatitis The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD) - Eczema Area and Severity Index (EASI) sco...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (1000 mg bid) in patients with type 2 diabetes inadequately controlled with metformin monotherapy To demonstrate that the HbA1c reduction with fixed dose combination therapy of vildagliptin and metformin (25/1000 mg bid) is superior to that with metformin monotherapy (1000 mg bid) after 24 weeks o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to check how safe, beneficial and tolerable the drug canakinumab, along with childhood vaccines, is for patients with crypoyrin associated periodic syndromes (CAPS) To assess the long-term efficacy of canakinumab with respect to the maintenance of treatment response in CAPS patients who completed the CACZ885D2307 study

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio multicéntrico, aleatorizado, ciego, controlado con placebo de 3 meses de duración para evaluar el efecto del tratamiento con fingolimod en la respuesta inmune después de la vacuna para la gripe estacional y la dosis de recuerdo de vacuna antitetánica en pacientes con formas recidivantes de esclerosis múltiple Es un estudio de investigación clínica para averiguar si el fármaco fingolimod (FTY729) es seguro en personas que padezcan esclerosis múltiple (EM) y que tengan previsto vacunarse contra la gripe esta...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study in patients with moderate to severe psoriasis with secukinumab To demonstrate that secukinumab has superior efficacy compared to placebo on the pruritus intensity VAS (the worst itching within a recall period of 24 hours as part of the Patients Global Assessment ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Evaluation of drug-drug interaction between LCZ696 and sildenafil in subjects with mild to moderate hypertension - To investigate the effect of LCZ696 on single dose pharmacokinetics of sildenafil in subjects with mild to moderate hypertension. - To investigate the effect of sildenafil on the steady-state pharm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overload A deferazirox továbbfejlesztett gyógyszerformájának (granulátum) hatásosságát és biztonságosságát, valamint a kezeléssel való együttműködést értékelő vizsgálat vastúlterhelésben szenvedő (2 ‒ < 18 éves) gyermekeknél 1. To evaluate both formulations on patient compliance, using stick pack/tablet count in ICT naive patients 2. To evaluate the change from baseline in serum ferritin at 48 weeks of treatment for both...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane to evaluate safety of everolimus (RAD001) in postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer after recurrence or progression following NSAIs treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune